A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)
The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) (liver cancer) and elevated baseline alpha-fetoprotein.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have a confirmed diagnosis of liver cancer or a diagnosis of cirrhosis and a tumor with imaging characteristics of liver cancer
Participants in the United States, European Union, Taiwan and Hong Kong must have previously taken a therapy other than sorafenib for the treatment of liver cancer
Participants in China must have previously taken sorafenib for the treatment of liver cancer
Participant must be willing to provide blood for research
Female participant must not be pregnant or breastfeeding and must also use highly effective contraceptive method during study participation, if not surgically sterile or postmenopausal
Male participant must be surgically sterile or compliant with a highly effective contraceptive method
Participants Must Not:
Participant must not have undergone a prior liver transplant
Participant must not have uncontrolled hypertension, HIV, AIDS, active or uncontrolled clinically serious infection, ongoing or recent drug abuse, uncontrolled thrombotic or bleeding disorder or a bowel obstruction
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo